To do this, clinical trials need to use consistent core outcomes. Therefore, HARMONY Alliance researchers are running several Delphi Surveys to compile Core Outcome Sets (COS) for specific blood cancers/Hematologic Malignancies.
All the Delphi Surveys have been completed for HARMONY and for HARMONY PLUS. Consensus Meetings took place in March, May and October 2022.
What are COS and why do we need help from patients, clinicians, regulators and drug developers?
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
